<html>
<head>
<title>Genitourinary/Renal System and Breasts</title>
</head>
<body>
  <h1><center>Genitourinary/Renal System and Breasts</center></h1>
<br>
  <b>Anuria, Oliguria, Polyuria, and Edema</b>
<Br>
  <b>Ensuresis/Incontinence, Prolapse and Pelvic Relaxation</b>
<br>
  <b>Urinary Frequency/Hesitancy, Dysuria, Urinary Retention</b>
<br>
  <b>Hematuria and Discolored Urine</b>
  <br>
  Which of the following can cause alkaline urine?
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. Respiratory acidosis</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. UTI</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. Cranberry juice</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. None of the above</label><br>
</form> 
  Answer: <p style="color:white"> <i> E. coli</i> can make urine more acidic, but <i> Proteus</i> or <i>Pseudomonas</i> produce urease, which causes urine to be more alkaline. Respiratory acidosis can also cause acidic urine; alkalosis can also cause alkaline urine.</p>
<br>
  <b>Amenorrhea and Vaginal Bleeding</b>
<br>
  <b>Urethral Discharge</b>
<br>
  <b>Pelvic Pain</b>
<br>
  <b>Vulvar and Vaginal Discharge, Lesions, and Pain</b>
<Br>
  <b>Penile, Scrotal, and Testicular Lesions, Masses, Pain, and Bleeding</b>
  <br>
  Which of the following conditions can gonorrhea cause if left untreated?
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. PID</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. Epididymitis</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. Both A and B</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. Neither A nor B</label><br>
</form> 
Answer: <p style="color:white"> Untreated gonorrhea can cause PID in women and epididymitis in men. Routine testing is recommended because some patients do not notice their symptoms.</p>
<br>
  <b>Pelvic, Prostate, and Renal Masses</b>
<br>
  <b>Breast Masses, Discharge, and Pain</b>
<br>
  <b>Physical Exam Findings Related to the Genitourinary/Renal System and Breasts</b>
<Br>
<b>Laboratory Test Findings and Diagnostic Imaging Related to the Genitourinary/Renal System and Breasts</b>
<br>
  <h2>Normal Processes</h2><br>
  <b>Embryonic development, fetal maturation, and perinatal changes</b><br>
  <b>Organ structure and function</b><br>
  <i>kidneys, ureters, bladder, urethra</i><br>
  <i>glomerular filtration and hemodynamics</i><br>
  Glomerular capillary hydrostatic pressure = 47 mmHg<br>
  Bowman space hydrostatic pressure = 10 mmHg <br>
  Bowman space oncotic pressure = 0 mmHg <br>
  At what value of glomerular capillary oncotic pressure would glomerular filtration stop?<br>
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. 57 mmHg</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. 47 mmHg </label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. 37 mmHg </label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. 10 mmHg</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. 0 mmHg</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> Glomerular filtration will stop when the net ultrafiltration pressure across the glomerular capillary is zero; that is, when the force that favors filtration (47 mmHg) exactly equals the forces that oppose filtration (10 mmHg + 37 mmHg)</p>
  The following information was obtained in a 20 yo college student participating in a research study in the Clinical Research Unit: <br>
  <b> Plasma </b> [Inulin] = 1mg/mL; [X] = 2 mg/mL <br>
  <b> Urine </b> [Inulin] = 150 mg/mL ; [X] = 100 mg/mL <br>
  Urine flow rate = 1mL/min
  Assuming that X is freely filtered, which of the following statements is most correct? <br>
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. There is net secretion of X</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. There is net reabsorption of X</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. There is both reabsorption and secretion of X</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. The clearance of X could be used to measure the GFR</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. The clearance of X is greater than the clearance of inulin</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
  Answer: <p style="color:white"> To answer this question, calculate the GFR and C<sub>X</sub>. GFR = (150 mg/mL x 1 mL/min) / 1 mg/mL = 150 mg/mL. C<sub>X</sub> = (100 mg/mL x 1 mL/min)/2 mg/mL = 50 mg/mL. Because the clearance of X is less than the clearance of inulin or GFR, net reabsorption of X must have occurred. Clearance data alone cannot determine whether there has also been secretion of X. Because GFR cannot be measured with a substance that is reabsorbed, X would not be suitable.</p>
  <i>urine concentration and dilution</i><br>
  A 58-year-old man is given a glucose tolerance test. In the test, the plasma glucose concentration is increased and glucose reabsorption and excretion are measured. When the plasma glucose concentration is higher than occurs at transport maximum (T<sub>m</sub>) the
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. clearance of glucose is zero</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. excretion rate of glucose equals the filtration rate of glucose</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. reabsorption rate of glucose equals the filtration rate of glucose</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. excretion rate of glucose increases with increasing plasma glucose concentrations</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. renal vein glucose concentration equals the renal artery glucose concentration</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
  Answer: <p style="color:white"> At concentrations greater than the transport maximum (T<sub>m</sub>) for glucose, the carriers are saturated so that the reabsorption rate no longer matches the filtration rate. The difference is excreted in the urine. As the plasma glucose concentration increases, the excretion of glucose increases. When it is greater than the T<sub>m</sub>, the renal vein glucose concentration will be less than the renal artery concentration because some glucose is being excreted in urine and therefore is not returned to the blood. The clearance of glucose is zero at concentrations lower than at T<sub>m</sub> (or lower than threshold) when all of the filtered glucose is reabsorbed but is greater than zero at concentrations greater than T<sub>m</sub>.</p>
  Which of the following would produce an increase in the reabsorption of isosmotic fluid in the proximal tubule? <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. Increased filtration fraction</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. ECF volume expansion</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. Decreased peritubular capillary protein concentration</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. Increased peritubular capillary hydrostatic pressure</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. Oxygen deprivation</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white">Increasing filtration fraction means that a larger portion of the renal plasma flow is filtered across the glomerular capillaries. This increased flow causes an increase in the protein concentration and oncotic pressure of the blood leaving the glomerular capillaries. This blood becomes the peritubular capillary blood supply. The increased oncotic pressure in the peritubular capillary blood is a driving force <i>favoring reabsorption</i> in the proximal tubules. ECF volume expansion, decreased peritubular capillary protein concentration,and increased peritubular capillary hydrostatic pressure all inhibit proximal reabsorption. Oxygen deprivation would also inhibit reabsorption by stopping the Na+-K+ pump in the basolateral membranes. </p>
  Which of the following substances or combinations of substances could be used to measure interstitial fluid volume?<br>
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. Mannitol</label><br>
  <input type="radio" id="B" name="1" value="B">
    <label for="female"> B. D<sub>2</sub>O alone</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. Evans blue </label><br>
  <input type="radio" id="D" name="1" value="D">
    <label for="other"> D. Inulin and D<sub>2</sub>O</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. Inulin and radioactive albumin</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> Interstitial fluid volume is measured indirectly by determining the difference between ECF volume and plasma volume. Inulin, a large fructose polymer that is restricted to the extracellular space, is a marker for ECF volume. Radioactive albumin is a marker for plasma volume.</p>
  <b>renal mechanisms in acid-base balance</b><br>
  To maintain normal H+ balance, total daily excretion of H+ should equal the daily<br>
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. fixed acid production plus fixed acid ingestion </label><br>
  <input type="radio" id="B" name="1" value="B">
    <label for="female"> B. HCO<sub>3</sub><sup>-</sup> excretion</label><br>
  <input type="radio" id="C" name="1" value="C">
    <label for="other"> C. HCO<sub>3</sub><sup>-</sup> filtered load</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. titratable acid excretion</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. filtered load of H+</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> Total daily production of fixed H+ from catabolism of proteins and phospholipids (plus any additional fixed H+ that is ingested) must be matched by the sum of excretion of H+ as titratable acid plus NH<sub>4</sub>+ to maintain acid-base balance.</p>
  A buffer pair (HA/A-) has a pK of 5.4. At a blood pH of 7.4, the concentration of HA is 
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. 1/100 that of A-</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. 1/10 that of A-</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. equal to that of A-</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. 10 times that of A-</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. 100 times that of A-</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> The Henderson/Hasselbalch equation can be used to calculate the ratio of HA/A- <br>
  pH = pK + log A-/HA <br>
  7.4 = 5.4 + log A-/HA<br>
  2.0 = log A-/HA <br>
  100 = A-/HA or HA/A- = 1/100</p>
  <b>renal mechanisms in body fluid homeostasis</b><br>
  A negative free-water clearance (-C<sub>H20</sub>) will occur in a person who
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. drinks 2L of distilled water in 30 minutes</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. begins excreting large volumes of urine with an osmolarity of 100 mOsm/L after a severe head injury</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. is receiving lithium treatment for depression and has polyuria that is unresponsive to the administration of ADH</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. has an oat cell carcinoma of the lung, and excretes urine with an osmolarity of 1000 mOsm/L</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. </label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> A person who produces hyperosmotic urine (1000 mOsm/L) will have a negative free-water clearance (-C<sub>H2O</sub>) [C<sub>H2O</sub> = V - C<sub>osm</sub>] All of the others will have a positive C<sub>H2O</sub> because they are producing hyposmotic urine as a result of the suppression of ADH by water drinking, central diabetes insipidus, or nephrogenic diabetes insipidus.</p>
  At plasma para-aminohippyuric acid (PAH) concentrations below the T<sub>m</sub>, PAH <br>
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. reabsorption is not saturated </label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. clearance equals inulin clearance</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. secretion rate equals PAH excretion rate</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. concentration in the renal vein is close to zero</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. concentration in the renal vein equals PAH concentration in the renal artery</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
  Answer: <p style="color:white"> At plasma concentrations that are lower than the T<sub>m</sub> for PAH secretion, PAH concentration in the renal vein is nearly zero because the sum of filtration plus secretion removes virtually all PAH from the renal plasma. Thus the PAH in the renal vein is less than that in the renal artery because most of the PAH entering the kidney is excreted in urine. PAH clearance is greater than inulin clearance because PAH is filtered and secreted; inulin is only filtered. </p>
Compared with a person who ingests 2L of distilled water, a person with water deprivation will have a <br>
  <form>
  <input type="radio" id="A" name="1" value="A">
    <label for="male"> A. higher C<sub>H2O</sub></label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. lower plasma osmolality</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. lower circulating level of ADH</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. higher tubular fluid/plasma osmolarity in the proximal tubule</label><br> <input type="radio" id="E" name="1" value="E">
    <label for="other"> E. higher rate of H<sub>2</sub>O reabsorption in the collecting ducts</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> The person with water deprivation will have a higher plasma osmolarity and higher circulating levels of ADH. These effects will increase the rate of H<sub>2</sub>O reabsorption in the collecting ducts and create a -C<sub>H2O</sub>. Tubular fluid/plasma osmolarity in the proximal tubule is not affeted by ADH.</p>
  Which of the following would cause an increase in both GFR and RPF?<br>
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. hyperproteinemia</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. a ureteral stone</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. dilation of the afferent arteriole</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. dilation of the efferent arteriole</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. constriction of the efferent arteriole</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> Dilation of the afferent arteriole will increase both RPF because renal vascular resistance is decreased, and GFR because glomerular capillary hydrostatic pressure is increased. Dilation of the efferent arteriole will increase RPF but decrease GFR. Constriction of the efferent arteriole will decrease RPF due to increased renal vascular resistance and increase GFR. Both hyperproteinemia (increased &pi; in the glomerular capillaries) and a ureteral stone (hydrostatic pressure in Bowman space) will oppose filtration and decrease GFR.</p>

Answer: <p style="color:white"> <table style="color:white">

Answer: <p style="color:white"> <table style="color:white">
Answer: <p style="color:white"> <table style="color:white">
  <b>micturition</b><br>
  <b>Cell/tissue structure and function</b><br>
  <i>renal metabolism and oxygen consumption</i><br>
  <i>tubular reabsorption and secretion, including transport processes and proteins</i><br>
  The reabsorption of filtered HCO<sub>3</sub><sup>-</sup>
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. results in reabsorption of less than 50% of the filtered load when the plasma [HCO<sub>3</sub><sup>-</sup>] is 24 mEq</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. acidifies tubular fluid to a pH of 4.4</label><br>
  <input type="radio" id="C" name="1" value="C">
    <label for="other"> C. is directly linked to excretion of H+ as NH<sub>4</sub>+</label><br>
  <input type="radio" id="D" name="1" value="D">
    <label for="other"> D. is inhibited by decreases in arterial P<sub>CO2</sub></label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. can proceed normally in the presence of a renal carbonic anhydrase inhibitor</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
  Answer: <p style="color:white"> Decreases in arterial P<sub>CO2</sub> cause a decrease in the reabsorption of filtered HCO<sub>3</sub><sup>-</sup> by diminishing the supply of H+ in the cell for secretion into the lumen. Reabsorption of filtered HCO<sub>3</sub><sup>-</sup> is nearly 100% of the filtered load and requires carbonic anhydrase in the brush border to convert filtered HCO<sub>3</sub><sup>-<sup></p> to CO<sub>2</sub> to proceed normally. This process causes little acidification of the urine and is not linked to net excretion of H+ as titratable acid or NH<sub>4</sub>+. 
  One gram of mannitol was injected into a woman. After equilibration, a plasma sample had a mannitol concentration of 0.08g/L. During the equilibration period, 20% of the injected mannitol was excreted in the urine. The woman's
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. ECF volume is 1L </label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. ICF volume is 1L </label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. ECF volume is 10L </label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. ICF volume is 10L </label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. interstitial volume is 12.5L </label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> Mannitol is a marker substance for the ECF volume. ECF volume = amount of mannitol/concentration of manitol = (1g - 0.2g)/0.08g/L = 10L </p>
<i>hormones produced by or acting on the kidney (eg, renin, aldosterone, angiotensin II,
  vasopressin)</i><br>
  
  <b>Repair, regeneration, and changes associated with stage of life</b><br>
<h2>Abnormal Processes: Health and Health Maintenance, Screening, Diagnosis, Management, Risks, Prognosis</h2><br>
  <h3>Infectious, immunologic, and inflammatory disorders</h3><br>
  <b>Infectious disorders</b><br>
<i>Upper urinary tract: granulomatous pyelonephritis; perinephric abscess;
  pyelonephritis; pyonephrosis; renal abscess; renal tuberculosis</i><br>
<i>Lower urinary tract and urinary tract infections of unspecified location: cystitis;
  chlamydial and nonchlamydial</i><br>
  <b>Immunologic and inflammatory disorders</b><br>
  <i>Upper urinary tract</i><br>
<i>glomerular disorders: Alport syndrome; glomerular disease due to hepatitis
B, C; glomerulonephritis, including poststreptococcal; IgA nephropathy;
lupus nephritis; minimal change disease; nephrotic syndrome; thin
  basement membrane disease</i><br>
<i>tubular interstitial disease: acute tubular necrosis (ATN); acute
  interstitial nephritis; papillary necrosis; HIV nephropathy</i><br>
  <i>Lower urinary tract: interstitial cystitis</i><br>
  <b>Neoplasms</b>
  <i>Benign neoplasms and cysts: polycystic kidney disease</i><br>
<i>malignant neoplasms: renal (eg, Wilms tumor/nephroblastoma, renal cell carcinoma,
renal tumors associated with congenital/hereditary conditions); urinary bladder and
  collecting system</i><br>
  <b>Signs, symptoms, and ill-defined disorders</b><br>
  <i>dysuria; hematuria; oliguria, anuria; proteinuria</i><br>
  <b>Metabolic and regulatory disorders</b><br>
  <i>acute kidney injury; renal insufficiency; azotemia,
uremic syndrome; chronic kidney disease, including end-stage renal disease;
cystinuria; Fanconi syndrome; hypertensive renal disease (renal complications of
    hypertension); renal calculi, ureteral calculi, nephrolithiasis; renal tubular acidosis</i><br>
  <b>Vascular disorders</b><br>
  <i>renal artery stenosis (atherosclerosis, fibromuscular dysplasia,
    nephrosclerosis); renal vein thrombosis; renal infarction</i><br>
  <b>Traumatic and mechanical disorders</b><br>
  <i>bladder rupture; neurogenic bladder; obstructive
uropathy; posterior urethral valves; renal laceration; renal vascular injury; ureteral
laceration/avulsion/disruption; urethral diverticulum; urethral/ureteral
obstruction/stricture/prolapse; urinary incontinence, including secondary enuresis;
    vesicoureteral reflux</i><br>
  <b>Congenital disorders</b><br>
  <i>double ureters/ureteral duplication/double collecting system;
horseshoe kidney; hydronephrosis/reflux; renal agenesis, renal hypoplasia, renal
    dysplasia; single kidney</i><br>
  <b>Adverse effects of drugs on the renal and urinary system</b><br>
  <i>ACE inhibitors; aminoglycosides;
amphotericin B; cisplatin; furosemide; gadolinium (nephrogenic systemic fibrosis);
heroin; iodinated contrast dye; lithium; NSAIDs; penicillins; sulfa drugs; tenofovir; drug-
    induced urinary retention</i><br>
  <b>Fluid, electrolyte, and acid-base balance disorders</b><br>
<i>fluid volume and electrolyte/ion disorders: fluid volume disorders; dehydration;
hypovolemia; volume overload; electrolyte disorders; hyponatremia, hypernatremia;
hypokalemia, hyperkalemia; hypocalcemia, hypercalcemia; hypophosphatemia,
  hyperphosphatemia; hypomagnesemia</i><br>
  Secretion of K+ by the distal tubule will be decreased by<br>
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. metabolic alkalosis</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. a high K+ diet</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. hyperaldosteronism</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. spironolactone administration</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. thiazide diuretic administration</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> Distal K+ secretion is decreased by factors that decrease the driving force for passive diffusion of K+ across the lumenal membrane. Because spironolactone is an aldosterone antagonist, it reduces K+ secretion. Alkalosis, a diet high in K+, and hyperaldosteronism all increase [K+] in the distal cells and thereby increase K+ secretion. Thiazide diuretics increase flow through the distal tubule and dilute the lumenal [K+] so that the driving force for K+ secretion is increased.</p>
  Jared and Adam both weigh 70kg. Jared drinks 2L of distilled water, and Adam drinks 2L of isotonic NaCl. As a result of these ingestions, Adam will have a <br>
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. greater change in ICF volume</label><br>
  <input type="radio" id="B" name="1" value="B">
    <label for="female"> B. higher positive free-water clearance (C<sub>H2O</sub>)</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. greater change in plasma osmolarity</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. higher urine osmolarity</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. higher urine flow rate</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
Answer: <p style="color:white"> After drinking distilled water, Jared will have an increase in ICF and ECF volumes, a decrease in plasma osmolarity, a suppression of ADH secretion, a positive free-water clearance, and will produce dilute urine with a high flow rate. Adam, after drinking the same volume of isotonic NaCl, will have an increase in ECF volume only and no change in plasma osmolarity. Because Adam's ADH will not be suppressed, he will have a higher urine osmolarity, a lower flow rate, and a lower C<sub>H20</sub> than Jared.</p>
<i>acid-base disorders: metabolic acidosis; metabolic alkalosis; respiratory acidosis; respiratory alkalosis; mixed acid-base disturbances</i><br>
  A 45-year-old woman develops severe diarrhea while on vacation. She has the following arterial blood values:<br>
  pH = 7.25<br>
  P<sub>CO2</sub> = 24 mmHg <br>
  [HCO<sub>3</sub><sup>-</sup>] = 10 mEq/L <br>
  Venous blood samples show decreased blood [K<sup>+</sup>] and a normal anion gap. <br>
  The correct blood diagnosis for this patient is
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. metabolic acidosis</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. metabolic alkalosis</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. respiratory alkalosis</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. respiratory alkalosis</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. normal acid-base status</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
  Answer: <p style="color:white"> An acid pH, together with decreased HCO3<sup>-</sup> and decreased P<sub>CO2</sub> is consistent with metabolic acidosis with respiratory compensation (hyperventilation). Diarrhea causes gastrointestinal loss of HCO<sub>3</sub><sup>-</sup> creating a metabolic acidosis.</p><br>
 A 45-year-old woman develops severe diarrhea while on vacation. She has the following arterial blood values:<br>
  pH = 7.25<br>
  P<sub>CO2</sub> = 24 mmHg <br>
  [HCO<sub>3</sub><sup>-</sup>] = 10 mEq/L <br>
  Venous blood samples show decreased blood [K<sup>+</sup>] and a normal anion gap. <br>
  Which of the following statements about this patient is correct?
  <form>
  <input type="radio" id="A" name="1" value="A">
  <label for="male"> A. She is hypoventilating</label><br>
  <input type="radio" id="B" name="1" value="B">
  <label for="female"> B. The decreased arterial [HCO<sub>3</sub><sup>-</sup>] is a result of buffering of excess H+ by HCO<sub>3</sub><sup>-</sup>.</label><br>
  <input type="radio" id="C" name="1" value="C">
  <label for="other"> C. The decreased blood [K+] is a result of intracellular H+ for extracellular K+.</label><br>
  <input type="radio" id="D" name="1" value="D">
  <label for="other"> D. The decreased blood [K+] is a result of increased circulating levels of aldosterone</label><br> <input type="radio" id="E" name="1" value="E">
  <label for="other"> E. The decreased blood [K+] is a result of decreased circulating levels of ADH</label><br> <input type="radio" id="F" name="1" value="F">
  <label for="other"> F. </label><br>
</form> 
  Answer: <p style="color:white"> The decreased arterial [HCO<sub>3</sub><sup>-</sup>] is caused by GI loss of HCO<sub>3</sub><sup>-</sup> from diarrhea, not by buffering of excess H+ by HCO<sub>3</sub><sup>-</sup>. The woman is hyperventilating as respiratory compensation for metabolic acidosis. Her hypokalemia cannot be the result of the exchange of intracellular H+ for extracellular K+, because she has an increase in extracellular H+ which would drive the exchange in the other direction. Her circulating levels of aldosterone would be increased as a result of ECF volume contraction, which leads to increased K+ secretion by the distal tubule and hypokalemia.</p>
  <h2>Normal Processes</h2><br>
<b>Embryonic development, fetal maturation, and perinatal changes, gametogenesis</b><br>
  <b>Organ structure and function</b><br>
  <i>female structure, including breast</i><br>
  <i>female function (eg, ovulation, menstrual cycle, puberty)</i><br>
  <i>intercourse, sexual response</i><br>
<b>Cell/tissue structure and function</b><br>
  <i>hypothalamic-pituitary-gonadal axis, sex steroids,
    and gestational hormones</i><br>
  <b>Reproductive system defense mechanisms and normal flora</b><br>
  <b>Repair, regeneration, and changes associated with stage of life</b><br>
<h2>Abnormal Processes: Health and Health Maintenance, Screening, Diagnosis,
  Management, Risks, Prognosis</h2><br>
  <h3>Breast</h3><br>
  <b>Infectious, immunologic, and inflammatory disorders</b><br>
  <i>breast abscess, inflammatory
    disease of breast, fat necrosis; mastitis; nipple discharge</i><br>
<b>Neoplasms</b> <br>
  <i>Benign and undefined neoplasms</i><br>
  <i>breast cyst, solitary; fibrocystic changes; fibroadenoma; hypertrophy of breast; intraductal papilloma</i><br>
  <b>malignant neoplasms (including screening)</b><br>
  <i>breast cancer; intraductal carcinoma; Paget disease of breast; phyllodes tumors</i><br>
  <h3>Female reproductive system</h3>
  <b>Infectious, immunologic, and inflammatory disorders</b><br>
  <i>bacterial vaginosis; Bartholin gland abscess; cellulitis, pelvic; candidiasis of the vulva or vagina; lichen sclerosus; sexually transmitted infections and exposure; cervicitis and endocervicitis; chancroid (Haemophilus ducreyi); genital herpes; gonorrhea (Neisseria gonorrhoeae); human papillomavirus infection, genital/venereal/anal warts, condylomata acuminata; lymphogranuloma venereum (Chlamydia trachomatis), non-lymphogranuloma venereum; pelvic inflammatory disease; Fitz-Hugh–Curtis syndrome; salpingitis and oophoritis; syphilis (Treponema pallidum); trichomoniasis (Trichomonas vaginalis); urethritis; vaginitis; vulvovaginitis</i><br>
  <b>Neoplasms of the cervix, ovary, uterus, vagina, and vulva</b><br>
  <i>Benign neoplasms and cysts</i><br>
  <i>abnormal Pap smear; benign neoplasm of ovary; endocervical and endometrial polyps; leiomyomata uteri; ovarian cyst
malignant and precancerous neoplasms: cervical cancer; HPV causing cancer; cervical dysplasia, HPV causing dysplasia; endometrial hyperplasia; endometrial/uterine cancer; gestational trophoblastic disease (hydatidiform mole); ovarian cancer; vulvar dysplasia and cancer</i><br>
  <b>Fertility and infertility</b><br>
  <i>Assisted reproductive techniques (ART); contraception (eg, oral contraceptives, IUD, vaginal cap, cervical sponge, diaphragm, implant, morning-after pill, male and female condoms); female infertility; gonadal dysgenesis 45,X (Turner syndrome); sterilization; tubal factors; infertility</i><br>
  <b>Menopause</b><br>
  <i>ovarian failure, premature menopause; perimenopause; premenopausal menorrhagia; postmenopausal atrophic vaginitis (vaginal atrophy); postmenopausal bleeding; vasomotor symptoms</i><br>
  <b>Menstrual and endocrine disorders</b><br>
  <i>abnormal uterine bleeding, including perimenopausal; absence of menstruation (primary amenorrhea, secondary
amenorrhea including undiagnosed pregnancy); anovulation; dysmenorrhea; endometriosis; hirsutism, virilization; mittelschmerz; pelvic pain; polycystic ovarian syndrome; postcoital bleeding; premenstrual syndrome</i><br>
  <b>Sexual dysfunction</b><br>
  <i>dyspareunia; orgasmic dysfunction; sexual desire/arousal
    syndrome; vaginismus</i><br>
  <b>Traumatic and mechanical disorders</b><br>
  <i>Asherman syndrome; chronic inversion of uterus; chronic pelvic pain syndrome; cystocele; imperforate hymen; injuries, wounds, and burns affecting the female reproductive system and injuries, wounds, burns, and blast injuries; ovarian torsion; pelvic relaxation; prolapse, vaginal walls, uterine, uterovaginal; rectocele; urethrocele</i><br>
  <b<Congenital disorders</b><br>
  <i>müllerian agenesis; uterus didelphys, bicornuate uterus; short cervix</i><br>
  <b>Adverse effects of drugs on the female reproductive system and breast</b><br>
  <i>antihistamines, H2-receptor blockers; benzodiazepines; beta-adrenergic blockers; hormone replacement; opioids; spironolactone; selective serotonin reuptake inhibitors; tricyclic antidepressants</i><br>
  <h2>Normal Processes</h2>
  <b>Embryonic development, fetal maturation, and neonatal changes, gametogenesis</b><br>
  <b>Organ structure and function</b><br>
  <i>structure, male genitalia and prostate</i><br>
  <i>function, male genitalia and prostate (eg, spermatogenesis, puberty)</i><br>
  <i>intercourse, orgasm, erection</i><br>
  <b>Cell/tissue structure and function</b><br>
  <i>including hypothalamic-pituitary-gonadal axis, sex
    steroids, and gestational hormones</i><br>
  <b>Reproductive system defense mechanisms and normal flora</b><br>
  <b>Repair, regeneration, and changes associated with stage of life</b><br>
<h2>Abnormal Processes: Health and Health Maintenance, Screening, Diagnosis,
  Management, Risks, Prognosis</h2><br>
  <h3>Infectious, immunologic, and inflammatory disorders</h3><br>
  <b>Infectious disorders</b><br>
  <i>balanitis; epididymitis; orchitis; prostatitis; sexually transmitted
infections and exposure; chancroid (Haemophilus ducreyi); genital herpes; gonorrhea
(Neisseria gonorrhoeae); human papillomavirus infection, genital/venereal/anal
warts, condylomata acuminata; lymphogranuloma venereum (Chlamydia
trachomatis); syphilis (Treponema pallidum); trichomoniasis (Trichomonas vaginalis);
    urethritis, chlamydial and nonchlamydial, nongonococcal</i><br>
  <b>immunologic and inflammatory disorders</b><br>
  <i>autoimmune hypogonadism</i>
  <b>Neoplasms</b><br>
  <i>malignant neoplasms, penile, prostate, testicular, breast</i><br>
  <b>Metabolic and regulatory disorders, including sexual dysfunction</b><br>
  <i>erectile dysfunction,
    impotence; infertility, male factor; male sexual dysfunction; premature ejaculation</i><br>
  <b>Traumatic and mechanical disorders</b><br>
  <i>benign prostatic hyperplasia/hypertrophy; circumcision,
including complications; epididymal cyst; hydrocele; injuries, wounds, and burns to male
genitalia, including blast injuries; penile laceration, penile fracture, Peyronie disease;
phimosis; scrotal laceration; spermatocele; testicular rupture/avulsion/laceration; torsion
    of testis; urethral laceration/disruption; varicocele</i><br>
  <b>Congenital disorders of the male reproductive system</b><br>
  <i>hypospadias; Klinefelter syndrome;
    undescended testicle</i><br>
  <b>Adverse effects of drugs on the male reproductive system</b><br>
  <i>alcohol; androgens, testosterone;
antipsychotics, antidepressants including selective serotonin reuptake inhibitors; betaadrenergic blockers; diuretic including thiazides; drug-induced priapism (eg, trazodone);
finasteride, dutasteride; sildenafil, tadalafil, vardenafil; marijuana; nitric oxide reductase
    inhibitors</i><br>
</body>
</html>
